吉非替尼治疗EGFR阳性Ⅲb~Ⅳ期非小细胞肺癌患者的效果及其对EGFR、P-Akt的影响  

Effect of Gefitinib in the Treatment of EGFR Positive StageⅢb-ⅣNon-small Cell Lung Cancer Patients and Its Influence on EGFR and P-Akt

作　　者：袁慧 徐洋 张娟 YUAN Hui;XU Yang;ZHANG Juan(Qidong Hospital of Traditional Chinese Medicine,Qidong 226200,China;不详)

机构地区：[1]启东市中医院,江苏启东226200

出　　处：《中外医学研究》2023年第1期45-48,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究吉非替尼治疗表皮生长因子受体(EGFR)阳性Ⅲb~Ⅳ期非小细胞肺癌患者的效果及其对EGFR、蛋白磷酸化Akt(P-Akt)的影响。方法:选取2018年1月-2021年6月启东市中医院收治的88例EGFR阳性Ⅲb~Ⅳ期非小细胞肺癌患者为研究对象。根据随机数字表法将其分为常规组(44例)和观察组(44例)。常规组给予注射用顺铂及注射盐酸吉西他滨,观察组在常规组的基础上给予吉非替尼片。比较两组治疗3个疗程后临床效果,治疗前后EGFR、P-Akt表达情况及不良反应。结果:观察组客观缓解率高于常规组(P<0.05)。治疗后,两组EGFR、P-Akt阳性率均低于治疗前(P<0.05),且观察组EGFR、P-Akt阳性率均低于常规组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:吉非替尼治疗EGFR阳性Ⅲb~Ⅳ期非小细胞肺癌患者,有利于改善客观缓解率,降低EGFR、P-Akt阳性率,且安全性好。Objective:To investigate the effect of Gefitinib in the treatment of epidermal growth factor receptor(EGFR)positive stageⅢb-Ⅳnon-small cell lung cancer patients and its influence on EGFR and phosphorylated Akt(P-Akt).Method:From January 2018 to June 2021,88 patients with EGFR positive stageⅢb-Ⅳnon-small cell lung cancer admitted to Qidong Hospital of Traditional Chinese Medicine were selected as research objects.According to the method of random number table,they were divided into routine group(44 cases)and observation group(44 cases).The routine group was given Cisplatin for Injection and Gemcitabine Hydrochloride for Injection,and the observation group was given Gefitinib Tablets on the basis of the routine group.The clinical efficacy after 3 courses of treatment,EGFR,P-Akt expression condition before and after treatment and adverse reactions of the two groups were compared.Result:The objective remission rate of the observation group was higher than that of the routine group(P<0.05).After treatment,the positive rates of EGFR and P-Akt in both groups were lower than those before treatment(P<0.05),and the positive rates of EGFR and P-Akt in the observation group were lower than those in the routine group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:In the treatment of EGFR positive stageⅢb-Ⅳnon-small cell lung cancer patients,Gefitinib is beneficial to improve the objective remission rate and reduce the positive rate of EGFR and P-Akt,with good safety.

关 键 词：吉非替尼 表皮生长因子受体 磷酸化AKT 非小细胞肺癌 阳性率 酪氨酸激酶 恶性肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]